Discovery of Potent and Selective Benzothiophene Difluoromethyl Phosphonate (DFMP) PTPN2/N1-Dual Inhibitors.
Zheng, X.M., Candito, D.A., Jewell, J., Childers, M., Kawamura, S., Logan, K.M., Otte, R.D., Yeung, C.S., Xiao, D., Liu, P., DeMong, D.E., Huang, C., Sanyal, S., McGowan, M., Levi, S.M., Schneider, S.E., Fradera, X., Palte, R.L., Lyons, T.W., Poremba, K.E., Miller, J.R., Chai, X., Xu, Z., Musisi, I., Mansueto, M.S., Venkataraman, S., Moy, L.Y., Zhang, M., Yang, Y., Cheng, M., McLeod, R., Laskey, J., Angagaw, M., Smith, D.M., Varkhede, N., Muise, E.S., Bass, A., Walraven, J., Doty, A., Yu, H., Rath, B., Engstrom, L., Wang, H., Follmer, N.E., Slavonic, M., Ehrenberger, T., Nicholson, B., Haining, W.N., Bennett, D.J., DiMauro, E.F., Machacek, M.R., Shumway, S.(2026) J Med Chem 69: 10515-10530
- PubMed: 42054654 Search on PubMed
- DOI: https://doi.org/10.1021/acs.jmedchem.5c03738
- Primary Citation Related Structures: 
9ZME, 9ZMF, 9ZMG, 9ZMH - PubMed Abstract: 
PTPN1 and PTPN2 are interesting targets for immuno-oncology due to their ability to modulate IFNγ signaling and T-cell activity. We report the discovery of benzothiophene difluoromethyl phosphonate (DFMP) inhibitors with potent dual PTPN1/PTPN2 activity. Structure-based design and a late-stage Ir-catalyzed C-H borylation enabled C5/C7-disubstituted designs that produced a marked inflection in potency. Systematic vector optimization improved potency, selectivity, and pharmacokinetic properties. Mechanistic studies identified SLC19A1 as a key transporter mediating cellular uptake. Lead compound 25 exhibited good potency, high selectivity, favorable PK, and dose-dependent pSTAT1 induction in a MC38 mouse model. These results establish compound 25 as promising structurally differentiated tool to study PTPN1/N2 inhibition and underscore the importance of SLC19A1 in the transport of DFMPs.
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States.
Organizational Affiliation: 
















